In 160,000 nondiabetic adults, GLP-1 users had 41% lower obesity-linked cancer risk

Obesity is a recognized risk factor for at least 13 types of cancer, and prior research has linked GLP-1 receptor agonist use to reduced cancer incidence in people with diabetes. Whether that association holds in people who are obese but don't have diabetes — an increasingly large share of GLP-1 users, given the drugs' expanding weight-management use — had not been specifically tested until a study published this month in Annals of Oncology [s1].

The design

Researchers used TriNetX, a database covering 113 million US patients, to conduct a target trial emulation — a method that uses observational data to approximate the design of a randomized trial [s1]. They identified obese, nondiabetic adults without a prior diagnosis of any obesity-associated cancer (OAC), treated between December 2014 and June 2025, and compared those prescribed a GLP-1 receptor agonist against those who received diet or exercise counseling instead, using 1:1 propensity score matching and inverse probability of treatment weighting to balance the two groups [s1]. The primary outcome was cumulative incidence of 13 obesity-associated cancers [s1]. Secondary analyses broke results down by sex, BMI category, race, and specific drug (semaglutide versus tirzepatide) [s1].

What it found

The full cohort included 229,467 patients, of whom 86,422 (37.7%) received a GLP-1 receptor agonist and 143,045 (62.3%) received diet or exercise counseling [s1]. After propensity score matching, the analysis cohort comprised 161,798 patients — 80,899 in each group [s1]. Mean age was 47.2 years, and median follow-up was two years [s1]. GLP-1 receptor agonist users had a significantly lower incidence of any obesity-associated cancer: hazard ratio 0.59 (95% CI 0.53–0.67) [s1]. The inverse probability weighting analysis confirmed the same pattern [s1]. In secondary analyses, the lower cancer incidence held across nearly every subgroup checked — sex, BMI category, and both drugs studied — with one notable exception: the association was not observed among Black patients [s1].

The racial subgroup gap is the finding that most needs follow-up

A hazard ratio of 0.59 — implying roughly a 41% relative reduction in obesity-associated cancer risk — is a substantial effect size for an observational study, and its consistency across sex, BMI, and drug type strengthens the overall signal. But the absence of the same protective association among Black patients specifically is a gap the study reports without explaining, and it's the detail most likely to matter for how this finding gets applied clinically. Possible explanations the study doesn't rule out include differences in cancer screening or detection rates, differences in comorbidities or cancer subtypes across racial groups, statistical power limitations within a smaller subgroup, or genuine biological differences in how GLP-1 drugs affect cancer risk pathways across populations — the data as reported here can't distinguish between these.

What this doesn't establish

This is an observational, propensity-matched analysis, not a randomized trial — even with statistical matching techniques designed to balance the two groups, unmeasured confounding remains possible, particularly confounding by indication (people prescribed a GLP-1 drug may differ from those given only counseling in ways that also affect cancer risk, independent of the drug itself). A median follow-up of two years is short for a cancer outcome, since many cancers take years to develop and be diagnosed after an exposure begins — this study can speak to short-term associations but not necessarily to what happens over five, ten, or twenty years of GLP-1 use. The study's own authors are explicit that "prospective trials are needed to confirm causality" [s1], a direct acknowledgment that this analysis establishes association, not proof of a protective causal effect.

Why this adds to a growing body of evidence

This finding sits alongside separate prior research linking GLP-1 drugs to reduced cancer risk in people with diabetes, extending the association specifically to obese patients without diabetes — a population that increasingly represents a large share of real-world GLP-1 prescriptions as the drugs' use for weight management alone has expanded well beyond their original diabetes indication.

What to watch

Whether the racial subgroup discrepancy is investigated and explained in follow-up research, and whether prospective, ideally randomized, data eventually clarifies whether the association reflects a genuine causal cancer-risk reduction. This article is not medical advice.

Sources

1. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults — Annals of Oncology, 7 June 2026